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Objective: The occurrence of psychiatric comorbidity among individuals with crack or
inhalant  dependence is frequently observed. The objective of this study was to investigate
anxiety  symptoms among crack cocaine and inhalant users in southern Brazil.
Methods: The study investigated two groups of volunteers of equal size (n = 50): one group
consisted  of crack cocaine users, and the other group consisted of inhalant users. Research
volunteers  completed the Portuguese versions of the State-Trait Anxiety Inventory (STAI),
Hamilton Anxiety Rating Scale (HAM-A), and Self-Report Questionnaire (SRQ).
Results: Both crack and inhalant users experience signiﬁcant symptoms of anxiety. Inhalant
users  presented signiﬁcantly more anxiety symptoms than crack users according to the
HAM-A  questionnaire only. In contrast to the results of the HAM-A, the STAI failed to
demonstrate  a signiﬁcant difference between the two groups of substance users. SRQ scores
revealed that crack and inhalants users had signiﬁcant degrees of morbidity.
Conclusion:  A signiﬁcant difference regarding anxiety symptomatology, especially state
anxiety,  was observed among inhalant and crack users. Anxiety and overall mental
psychopathology were signiﬁcantly correlated in this sample. The results indicate that
screening initiatives to detect anxiety and additional psychiatric comorbidities among crack
and inhalant users are feasible and relevant.
Sintomas  de  ansiedade  em  usuários  de  crack  e  inalantes  admitidos
em  uma  unidade  psiquiátrica  na  Região  Sul  do  Brasil
r  e  s  u  m  o
© 2013 Elsevier Editora Ltda. Este é um artigo Open Access sob a licença de CC BY-NC-NDPalavras-chave:
Crack
Solventes
Objetivo: Investigar sintomas de ansiedade em usuários de crack e inalantes no Sul do Brasil.
Métodos:  O estudo investigou dois grupos de voluntários com o mesmo  número de indivíduos
(n  = 50): um grupo consistiu de usuários de crack e o outro grupo, de usuários de inalantes.
 Study conducted at Universidade de Caxias do Sul and Clínica Paulo Guedes, Caxias do Sul, RS, Brazil.
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Ansiedade
Brasil
Questionários
Os voluntários da pesquisa completaram as versões em português das escalas de ansiedade
State-Trais Anxiety Inventory (STAI) e Hamilton Anxiety Rating Scale (HAM-A), e o Questionário
de Autoavaliac¸ão  (SRQ).
Resultados:  Ambos os grupos apresentaram sintomas signiﬁcativos de ansiedade. Os
usuários de inalantes apresentaram escores quanto a HAM-A signiﬁcativamente superiores
aos usuários de crack. Ansiedade e psicopatologia geral se apresentaram signiﬁcativamente
correlacionados.
Conclusão: Sintomas de ansiedade são frequentes entre usuários de crack e inalantes. Um
processo de triagem de sintomas de ansiedade entre usuários de crack e inalantes deve
facilitar ainda mais as intervenc¸ões  terapêuticas nesta área.
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13 Entroduction
rack and inhalant abuse have been documented as two of the
ost  common addictive disorders in Brazil.1,2 Crack cocaine
nd  inhalants have been used in Brazil by street children,3
ndergraduates,4 and medical students.5,6 Inhalants abuse
nd  dependence negatively affect youth regardless of gender,
thnicity,  age, and family income.7 The association between
nhalant  dependence and other psychiatric morbidities is
igher  than in patients with dependence to other psychoac-
ive  drugs, including alcohol.8
The co-occurrence of mood and anxiety disorders has been
redominantly associated with adverse outcomes among
oung  substance users.9 The prevalence ﬁgures of anxiety
isorders among substance users vary according to differ-
nt  studies.10 In the Drug Abuse Treatment Outcome Study
DATOS),  which assessed over 10,000 substance users, the
revalence  of generalized anxiety disorder (GAD) ranged from
.2%  to 4.2%,11 while in studies with smaller sample sizes the
revalence  rates of anxiety disorders varied substantially.12–14
ymptoms of anxiety were  also the most common psychiatric
anifestation among adolescents with substance use-related
isorders (60% of both boys and girls).15 The signiﬁcant asso-
iation  between any anxiety disorder and lifetime cocaine use
as been consistently detected in an independent survey con-
ucted in the US and Canada.16 In a Spanish cross-sectional
tudy, nearly 42.5% of cocaine users recruited in non-clinical
ettings presented with a psychiatric comorbidity; anxiety
isorders (13%) were the second most common comorbid
isorder, after depression.17 Data from an international mul-
icenter  study revealed that the onset of anxiety disorders
sually precedes the initiation of substance use disorders.18
The use of cocaine may  precipitate panic attacks, phobia
eactions, obsessions, and compulsions, which may  persist
fter  discontinuation of use.19,20 The comorbidity between
ocaine use and social phobia21 and post-traumatic stress
isorder (PTSD)22,23 tends to occur among individuals with
evere  cocaine use, with personal background and family
istory  of psychiatric disorders.24 The association between
nxiety disorder and cocaine use has been described in the
ontext  of affective disorder,25,26 and documented extensively
mong people with panic attacks.27–29 Treatment-seeking
14
© 20ocaine users also report signiﬁcant levels of anxiety. Anx-
ety  and mood disorders were  the most common comorbid
xis  I disorders diagnosed in a sample of male inpatients in
owa.30 Anxiety is also a prominent clinical feature during theabstinence phase of cocaine withdrawal.31 In comparison with
users  of heroin only, users of both heroin and cocaine present
signiﬁcantly more  symptoms of anxiety.32 Anxiety has also
been  considered as a risk factor for the occurrence of cocaine-
induced  paranoia.33
Anxiety disorders are commonly associated with inhalant
use.  The reported prevalence rate of generalized anxiety dis-
order  among inhalant users is 20.5%.8 Data from a national
epidemiological survey revealed that inhalant users had a
signiﬁcant  lifetime prevalence of anxiety disorders (36%).34
Female inhalant users presented higher lifetime prevalence
rates  of any anxiety disorder in comparison with male users
(53%  versus 30%), including panic disorder without agora-
phobia  (25% versus 11%), and speciﬁc phobia (28% versus
14%).  Female inhalant users also were more  likely to have
met  the criteria for three or more  anxiety disorders (15%
versus  8%) in the past year.34 In addition, adolescents with
inhalant abuse or dependence are signiﬁcantly more  likely to
have abuse or dependence of alcohol, hallucinogens, nicotine,
cocaine,  and/or amphetamines, and are more  likely to have
attempted  suicide compared with other adolescent patients
who  reported never using inhalants.35 Toluene is the main
component of inhalants used by youth in Brazil, including
homeless youth, as conﬁrmed by urinary levels of hippuric
acid.36,37
Considering the frequent occurrence of psychiatric comor-
bidity  among individuals with crack or inhalant dependence,
as  well as the compounding and detrimental effects of this
association, it is essential to carefully screen these drug
users  for anxiety.35,38 Furthermore, the majority of individuals
affected by anxiety disorders have never obtained effective
treatment despite the signiﬁcant level of disability imposed by
these conditions.39 The objective of this study was  to inves-
tigate  anxiety symptoms among crack cocaine and inhalant
users  in southern Brazil. To the authors’ knowledge, this is
the  ﬁrst time that crack and inhalant users have been simul-
taneously  assessed with two anxiety-speciﬁc measures in
southern  Brazil.
Methods
Sample
lsevier Editora Ltda. Este é um artigo Open Access sob a licença de CC BY-NC-NDThe study investigated two groups of volunteers of equal size
(n  = 50): one group consisted of crack cocaine users and the
other  group consisted of inhalant users. Both groups were
 a s . 2362  r e v a s s o c m e d b r
interviewed as inpatient volunteers in wards  of a tertiary care
mental  health facility and a higher education training site
associated  with the Universidade de Caxias do Sul. Drug users
fulﬁlled  the Diagnostic and Statistic Manual of Mental Disor-
ders,  4th edition (DSM-IV) diagnostic criteria for crack cocaine
or  inhalant dependence, according to a psychiatric interview
conducted upon admission by psychiatrists who were com-
pletely  unfamiliar with this research protocol. Patients with
polydrug  dependence had to satisfy the inclusion criteria of
using  either crack cocaine or any type of inhalant drug as (a)
the  main addictive substance, and (b) the one causing the most
salient  dependence.
All  patients who  volunteered to participate in this inves-
tigation were  assisted via the Brazilian public health system.
Taking  into account that a substantial fraction of the sam-
ple  was  illiterate or semi-illiterate, all drug users completed
the  questionnaires under minimal guidance by trained inter-
viewers,  who  followed standardized instructional procedures.
Uncompleted or inappropriately completed questionnaires
were  excluded from analysis. All volunteers spoke Portuguese
as  their ﬁrst language.
Informed  consent  and  recruitment
This study was  endorsed by the institutional Ethics and
Research  Committees of the Universidade de Caxias do
Sul  (UCS), which regulate all scientiﬁc activities at UCS.
All  volunteers signed a informed consent. A certiﬁcate of
conﬁdentiality was  guaranteed to all research participants.
Consent from parents or legally responsible adults was
obtained  before minor participants were  formally enrolled in
the present study. All respondents were treated anonymously.
Research participants were recruited via word-of-mouth. Drug
users were  approached to participate in this study after having
achieved  a stable clinical course, as determined by their own
physician.  The recruitment process took place during various
consecutive months, according to the rate of hospital admis-
sions  of prospective participants. Research participants were
interviewed  only once for the purpose of this investigation.
Research  tools
The State-Trait Anxiety Inventory (STAI) is one of the most
widely  used self-report measures of anxiety in clinical and
research  settings.40 The STAI measures two different compo-
nents:  state anxiety, which refers to a transitory and subjective
emotional state that varies over time; and trait anxiety, which
refers  to a relatively stable pattern of reaction to stress with
anxiety  and a tendency to perceive situations as threatening.41
The Portuguese version of the STAI was  validated in a sample
of  university students in Brazil.42 Each part varies from 20 to
80  points, and the scores indicate low (0–30), medium (31–49),
or  high (50 or more)  anxiety levels.41
The Hamilton Anxiety Rating Scale (HAM-A) was  conceived
as  an easy-to-use instrument to measure state anxiety.43 The
HAM-A  has been used extensively to investigate symptoms of
anxiety  as well as the result of interventions aimed at reduc-
ing  levels of anxiety.44 The Portuguese version of the HAM-A
has  been widely used for measuring mainly state anxiety.45
A score of 17 or below indicates absence of or low levels of 0 1 3;5  9(4):360–367
anxiety;  a score from 18 to 24 indicates low to moderate anx-
iety  levels; while a score from 25 to 30 indicates moderate to
severe  anxiety levels.46
The Self-Reporting Questionnaire (SRQ) was  used to iden-
tify  minor and general psychiatric morbidity.47 The SRQ was
derived  from research instruments used by the World Health
Organization (WHO) for studying psychiatric morbidity in pri-
mary care settings in developing countries.48,49 According to
SRQ,  respondents were classiﬁed as high (≥ 8) or low (≤ 7)
scorers.50
The socio-economic status (SES) of research participants
was  assessed via a scale previously tested in Brazil.51 This
instrument classiﬁes SES into six categories: lower-lower,
upper-lower, lower-middle, upper-middle, lower-upper, and
upper-upper  class.
Statistical  analyses
Analysis of demographic variables was  performed in rela-
tion  to age and socioeconomic status. The overall scores of
the  HAM-A, STAI, and SRQ were computed and subsequently
transformed into Z-scores for correlation and regression anal-
yses.  Student’s t-test for independent samples was performed
to  examine differences between two groups of drug users.
Analyses of correlation via Pearson’s product-moment and
Spearman’s  rank coefﬁcients were  computed between the
questionnaires’ scores and categories, respectively. Logistic
regression analyses were also conducted to explore predictive
effects  of anxiety scales (HAM-A and STAI) on general psy-
chopathology (SRQ). Statistical analyses were conducted using
the  Statistical Package for Social Sciences (SPSS®).
Results
Demographic  data
The mean age in the overall sample was  20.2 years of age. The
mean  ages in the groups of crack users and inhalant users
were  22.8 and 17.3 years of age, respectively. Regarding gen-
der,  the overall sample had 12% and 88% of female and male
volunteers, respectively. Table 1 shows a summary of all demo-
graphic  information.
Regarding SES, most of the total sample was  classiﬁed
as upper-lower class (30%) and lower-middle class (59%). A
nonparametric analysis via Kruskal-Wallis test of the two
subgroups  differentiated according to SES strata revealed an
absence of a signiﬁcant difference in the medians between the
two  groups, with 2 (1, n = 100) = 2.15, p = 0.142.
Anxiety
The mean scores of the both anxiety rating scales used in
this  study (HAM-A and STAI), in the combined sample of
crack  and inhalant users and in each separate group are
shown  in Table 2. According to the HAM-A classiﬁcation,
71.7% of the sample did not have or had low levels of anx-
iety,  while 28.3% presented anxiety. Considering each group
separately,  crack users and inhalants users presented the fol-
lowing  results, respectively: 90% and 53.1% (absence or low
r e v a s s o c m e d b r a s . 2 0 1 3;5  9(4):360–367  363
Table 1 – Sociodemographic characteristics of the total sample of substance users
Sociodemographic characteristics Total (n = 100) Crack (n = 50) Inhalant (n = 50)
Age
Mean (± SD) 20.1 (6.2) 22.8 (6.4) 17.3 (4.5)
Range 29 (11-40) 17 (11-28) 25 (15-40)
Gender
Male 88 43 (86%) 45 (90%)
Female 12 7 (14%) 5 (10%)
Socio-economic status
Lower-lower 3 1 (2%) 2  (4%)
Upper-lower 32 15 (30%) 17 (34%)
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evels of anxiety), and 10% and 46.9% (presence of anxiety).
mong  crack users who  experienced anxiety, 4% presented
ight  to moderate levels of anxiety, while 6% presented mod-
rate  to severe levels of anxiety. Among inhalant users who
xperienced  anxiety, 28.6% reported light to moderate levels
f  anxiety, while 18.4% presented moderate to severe levels of
nxiety.
The  STAI classiﬁed crack and inhalant users, in terms of
resence  or absence of anxiety, taken together, as follows: 9%
absence or low levels of anxiety) and 91% (presence of anx-
ety).  The distribution according to the presence or absence
f  anxiety as classiﬁed by the STAI in the groups of crack
nd  inhalant users, respectively, was  as follows: 14% and 4%
absence  or low levels of anxiety), and 86% and 96% (pres-
nce  of anxiety). Among crack users who  experienced anxiety,
2%  presented medium levels of anxiety, while 14% presented
igh  levels of anxiety. Among inhalant users who experienced
nxiety,  78% reported medium levels of anxiety, while 18%
resented  high levels of anxiety.
A parametrical analysis using Student’s t-test for inde-
endent samples revealed a signiﬁcant statistical difference
etween the two groups of drug users according to the scores
f  the HAM-A anxiety ratings scale: t (97) = −4.62, p < 0.001.
 nonparametric analysis using the Mann-Whitney test of
AM-A  scores according to a categorical distinction (absence
r  presence of anxiety, based on a cut-off point of > 17, as
xplained  in the Methods section) also revealed a signiﬁcant
ifference among the groups of crack and inhalant users, with
 = −4.06, p < 0.001. This signiﬁcant difference persisted when
he  three different categories of intensity were taken into
ccount  (z = −3.9, p < 0.001).
A parametrical analysis using Student’s t-test for indepen-
ent  samples revealed an absence of signiﬁcant statistical
Table 2 – Scores and case details of crack and inhalants users a
HAM-A 
Mean (SD) Absence/low levels
of  anxiety (%)
Presenc
anxiety
Crack (n = 50) 8.38 (8.07) 90 10 
Inhalant (n = 50) 16.45 (9.28) 53.1 46.
Both groups 12.37 (9.54) 71.7 28.
HAM-A, Hamilton Anxiety Rating Scale; STAI, State-Trait Anxiety Inventor28 (56%) 29 (58%)
6 (12%) 2 (4%)
difference between the two groups of drug users according to
the STAI scores: t (98) = -1.54, p = 0.13. A nonparametric analy-
sis  using the Mann-Whitney test of STAI scores according to a
categorical distinction (absence or presence of anxiety, based
on  a cut-off point of ≥ 31, as explained in the Methods section)
also  revealed an absence of signiﬁcant difference between the
groups  of crack and inhalant users, with z = −1.74, p = 0.8. The
absence  of signiﬁcant difference persisted when the different
categories  of intensity were analyzed (z = −1.37, p = 0.17).
Correlation  analyses
Pearson product-moment correlation coefﬁcients were com-
puted  among the overall scores of all questionnaires
completed by the three groups. The Bonferroni method was
used  to control for type I error for all pair wise comparisons:
PC = 0.05/3 = 0.17.
A signiﬁcant correlation was  found between the scores of
the  HAM-A and the scores of the STAI in the combined sample
of  drug users (r = 0.43, p < 0.001). Spearman’s rank correlation
analysis also revealed a signiﬁcant association between the
caseness  (presence or absence of anxiety) generated by the
HAM-A  and the STAI ( = 2; p < 0.05).
Signiﬁcant correlations were  also found between the scores
of  HAM-A and SRQ (r = 0.44, p < 0.001) and between the scores
of  STAI and SRQ (r = 0.67, p < 0.001).
Linear  regression  analysesBivariate linear regression analyses were conducted, sepa-
rately,  to evaluate the prediction of general psychopathology
scores (SRQ) according to the scores of the anxiety rating scales
among  crack and inhalant users.
ccording to the HAM-A and the STAI questionnaires
STAI
e of
 (%)
Mean (SD) Absence/low levels
of  anxiety (%)
Presence of
anxiety  (%)
48.06 (10.52) 14 86
9 51 (8.39) 4 96
3 49.53 (9.58) 9 91
y.
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Fig. 1 – Scatter plots demonstrating the linear correlation
between the SRQ (general psychopathology) and the STAI
and  HAM-A (anxiety) questionnaires.
SRQ, Self-Report Questionnaire; STAI, State-Trait Anxiety
Inventory; HAM-A; Hamilton Anxiety Rating Scale.An initial analysis to predict changes in the SRQ scores,
having the HAM-A scores as a predictor, revealed that the
two  variables were linearly related, such that as the overall
anxiety  symptomatology increases, the magnitude of gen-
eral  psychopathology also increases. The linear predictive
ability was  signiﬁcant (95% CI: 0.32-0.67). Approximately 24%
of the variance of the SRQ scores was  accounted for by its
linear  relationship with the HAM-A. A similar linear regres-
sion  analysis was  conducted to evaluate the prediction of
the  SRQ scores using the STAI scores as a predictor. The
results  indicated that the SRQ scores and the STAI scores
are  also linearly related. The correlation was  signiﬁcant (95%
CI:  0.52-0.82). Approximately 45% of the variance of the SRQ
score  was  accounted for by its linear relationship with the
STAI.
The  scatter plots of the two bivariate linear regression anal-
yses  mentioned above are presented in Fig. 1. 0 1 3;5  9(4):360–367
Discussion
The results presented in this study indicate that both crack
and  inhalant users experience signiﬁcant symptoms of anxi-
ety.  The prevalence of anxiety among crack users varies from
10%  (HAM-A) to 86% (STAI), while among inhalant users the
ﬁgures  vary from 46.9% (HAM-A) to 96% (STAI). Crack users
presented  signiﬁcantly more  anxiety symptoms than inhalant
users  according to the HAM-A questionnaire only. This differ-
ence  was  observed when results were treated parametrically
and non-parametrically. These ﬁndings are consistent with
results  obtained by other studies, which revealed that anxiety
is,  among other psychiatric symptoms, a frequent comor-
bidity  among crack cocaine users.17 Crack cocaine users, in
particular,  are known to present with signiﬁcant psychiatric
comorbidities, including depression, anxiety disorders, bipo-
lar  disorder, and attention-deﬁcit/hyperactivity disorder, with
eventual  fatal outcomes.52,53 In Brazil, treatment-seeking non-
intravenous cocaine users presented a lifetime prevalence
of  Axis I or Axis II disorders of 69%, and anxiety disor-
ders were the most common psychiatric disorder (31%).54
The higher prevalence of anxiety disorders among cocaine
dependent subjects encompasses different dysfunctions such
as general anxiety, phobic, panic, and obsessive-compulsive
disorders.55 Although the physiological and psychoactive
effects of cocaine are similar regardless of its hydrochloride
or  crack form, evidence indicates a greater abuse liability and
propensity  for dependence, as well as more  severe conse-
quences, when cocaine is smoked or injected intravenously
in  comparison with intranasal use.56 In Brazil, a signiﬁcant
tendency to change routes of administration and patterns of
cocaine  use has been documented by several studies in the
last  decade.1,44,57–60
Contrarily to the results of the HAM-A, the STAI failed
to  demonstrate a signiﬁcant difference between the two
groups  of substance users. There are conceptual differences
between the two scales used to evaluate anxiety in this
sample.  The HAM-A measures state anxiety, which is a symp-
tomatic  expression, while the STAI also captures trait anxiety,
which  is related to characteriological issues.45 The differences
between “state” and “trait” anxiety reﬂect the conceptual dis-
tinction between existing anxiety as a transitory state and the
anxiety  as a relatively stable personality characteristic.61,62
STAI scores may suffer from being inﬂuenced by different
illness variables, such as severity, chronicity, and comorbid-
ity  of symptoms.63 Although variations in ratings have been
reported  with the HAM-A as well,64,65 the STAI was  unable to
distinguish  between anxiety and depression in a mixed group
of  patients with both conditions, from which the authors con-
cluded  that the STAI does have clinical utility for measuring
emotional distress.63 In the present study, only the trait subset
of  the STAI was  used. The results of this study suggest there-
fore  that trait anxiety is not signiﬁcantly affected by crack and
inhalant  use, and that only measures of state anxiety should
be  used for the assessment of anxiety related to cocaine and
inhalant  use.Considering the contrasting results produced by differ-
ent  scales used to measure anxiety, there is an increased
need to investigate possible differences in the symptomatic
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easurement among patients with anxiety.63 Although psy-
hometric  measures have been produced extensively in
sychiatry,  sometimes via a single assessment tool, it has
een  advocated that anxiety and depression may  be similar
lements  of a general psychological distress experience of dif-
cult differentiation.66 Likewise, depression is a disorder with
mportant  clinical signiﬁcance among crack cocaine users. A
revious study detected a lifetime prevalence of 17.8% for
epression  among crack cocaine users.67 Prevalence of depres-
ion  among crack users is believed to be higher than what has
een  previously reported.68 Furthermore, studies that investi-
ated  depressive disorders among crack users have detected
dditional  psychiatric comorbidities, including anxiety, bipo-
ar  disorder, and attention-deﬁcit/hyperactivity disorder, with
ventual  fatal outcomes.52,53
Regarding psychiatric morbidity, the scores generated by
he  SRQ revealed that crack and inhalants users had signiﬁ-
ant  degrees of morbidity. The SRQ has been previously used
s  general screening tool for mental disorders in the context
f  substance abuse.69–72 Furthermore, in a community-based
tudy conducted in southern Brazil, in which 126 adoles-
ents  were  screened for mental problems, the prevalence
f  depressive symptoms, suicidal ideation, and hopelessness
ere  higher among those who were detected as SRQ-positive
ccording to a cut-off score of ≥ 8,73 the same threshold used
n  the present study.
The  results of Pearson correlation analyses also revealed a
igniﬁcant correlation among anxiety symptoms and general
sychopathology, which attest to a congruent measurement
f  the constructs investigated in this study. Furthermore,
he results of the bivariate linear regression analyses also
evealed  that the scores of the two anxiety rating scales
sed  in this study can predict, with signiﬁcant accuracy,
he  scores of general psychopathology of crack and inhalant
sers.
Previous  evidence, based on regression analyses of data
rom  a national survey in the United States, revealed that
nhalant  users had greater odds of intravenous drug use
han  users who  had not used inhalants.34 The results pre-
ented  here reveal a direct and predictive association between
epressive  symptoms and general mental disorder among
rack  and inhalant users. Although additional studies are
equired  to further substantiate these ﬁndings, these results
ay  recommend more  rigorous and extensive screening
fforts to detect and treat depressive symptoms among crack
nd  inhalant users.
This  study may  present some limitations, especially in rela-
ion  to the nature of the sample investigated. Some of these
iscrepancies were  revealed in the analyses of demographic
ata. Firstly, regarding age range, inhalant users presented
 lower mean age in comparison with crack users. The rea-
ons  for the early age of inhalant use are based on the
act  that many  organic solvents are present in wide array
f  chemical compounds publicly commercialized for a broad
ariety  of household purposes, which facilitate children’s
ccess. In fact, inhalant use has been characterized as pref-
rentially  prevalent among children and juveniles in both
eveloped  and developing economies.74–79 In Brazil, as well
s  in other developing countries, inhalants tend to be the
referred  drug used among the street children, who are who1 3;5  9(4):360–367  365
live and wander unsupervised on the streets of major urban
centers.80
Secondly, male participants predominated signiﬁcantly in
both  groups. Evidence based on a series of surveys conducted
with  Brazilian secondary school students demonstrated an
increased  use of illicit psychotropic drugs by males, while
women  prefer to use drugs in the form of pills, such as anxi-
olytics  and amphetamines.81
Thirdly, the psychometric tools used in this study were  not
speciﬁcally  designed to evaluate adolescents. Although the
mean  age in the overall sample was  20.1 years, the mean age
of  inhalant users was  17.3 years. Nevertheless, most of the
instruments used in this study have been tested previously
as  screening tools among adolescents in southern Brazil.73
Furthermore, the unavailability of versions validated in Por-
tuguese  of instruments developed speciﬁcally for assessing
adolescents’ mental health prevented, at this stage, the use
of  a more  suitable methodology for this sample. This limita-
tion  highlights the need for validation studies of psychometric
instruments among adolescents in Brazil.
Despite the above-mentioned limitations, the sample
investigated in this study was recruited in public health facil-
ities,  where members of all socio-economic strata of the
Brazilian  society have prompt access to health care. This
advantage is particularly relevant in the case of a study con-
ducted  in a developing economy, where inequalities of care
are  known to produce signiﬁcant health differentials.82
Conclusion
A signiﬁcant difference regarding anxiety symptomatology,
especially state anxiety, was  observed among inhalant and
crack  users. Anxiety and overall mental psychopathology were
signiﬁcantly correlated in this sample. The results indicate
that  screening initiatives to detect anxiety and additional psy-
chiatric  comorbidities among crack and inhalant users are
feasible  and relevant. Considering that drug abuse, especially
of  inhalants, affect youth preferentially, and that adolescence
is  a vulnerable life cycle phase, the present ﬁndings justify
more  rigorous and extensive screening efforts to detect and
treat  anxiety disorders among crack cocaine and inhalant
users.
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